Ganga Pharmaceuticals Complete Financial Statements
In FYNone, Ganga Pharmaceuticals (GANGAPHARM) reported revenue ₹2 Cr, net profit ₹0 Cr and EPS ₹0.10. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Analyse GANGAPHARM promoter holding to track promoter, FII and institutional holdings.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
GANGAPHARM Revenue, Net Profit & EBITDA — Year-on-Year Growth
GANGAPHARM YoY (March 2026 vs Period) — revenue -33.3%, expenses -66.7%. For live price, earnings ratios and company overview, see Ganga Pharmaceuticals share price screener.
GANGAPHARM Income Statement — Revenue, EBITDA & Net Profit
Ganga Pharmaceuticals revenue ₹2 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.10 (None). Also explore GANGAPHARM price movement history to track price trends across different timeframes.
| Particulars | None | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 |
| Expenses | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 2 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Operating Profit Margin % | -2.00% | 1.00% | -4.00% | 2.00% | 0.00% | 2.00% | 1.00% | 13.00% | 12.00% | 11.00% | 10.00% | 12.00% | 9.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Earnings Per Share (₹) | 0.10 | 0.17 | 0.16 | 0.11 | 0.10 | 0.09 | 0.05 | 0.46 | 0.46 | 0.23 | 0.18 | 0.12 | 0.00 |
GANGAPHARM Balance Sheet — Assets, Liabilities & Shareholders' Equity
GANGAPHARM total assets ₹10 Cr, total equity ₹8 Cr, total liabilities ₹ Cr (2026).
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 7 | 5 |
| Current Assets | 8 | 7 | 6 | 5 | 5 | 5 | 4 | 4 | 5 | 4 | 5 | 2 |
| Fixed Assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 8 | 8 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 5 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 8 | 7 | 7 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 3 |
| Share Capital | 6 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 2 |
| Reserves & Surplus | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
GANGAPHARM Cash Flow Statement — Operating, Investing & Financing
Ganga Pharmaceuticals operating cash flow ₹-1 Cr, investing ₹1 Cr, financing ₹0 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 |
| Investing Activities | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | -1 | 0 |
| Financing Activities | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |